company background image
BNN logo

BRAIN Biotech DB:BNN Stock Report

Last Price

€3.49

Market Cap

€77.6m

7D

1.2%

1Y

-11.2%

Updated

01 Jan, 2025

Data

Company Financials +

BRAIN Biotech AG

DB:BNN Stock Report

Market Cap: €77.6m

BNN Stock Overview

Engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. More details

BNN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Earnings are forecast to grow 68.21% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Does not have a meaningful market cap (€78M)


My Notes

Capture your thoughts, links and company narrative

BRAIN Biotech AG Competitors

Nabaltec

XTRA:NTG

€118.8m

H&R GmbH KGaA

XTRA:2HRA

€126.2m

Uzin Utz

XTRA:UZU

€245.2m

AlzChem Group

XTRA:ACT

€580.1m

Price History & Performance

Summary of share price highs, lows and changes for BRAIN Biotech
Historical stock prices
Current Share Price€3.49
52 Week High€4.40
52 Week Low€1.42
Beta1.2
1 Month Change11.86%
3 Month Change31.70%
1 Year Change-11.20%
3 Year Change-63.11%
5 Year Change-68.56%
Change since IPO-66.76%

Recent News & Updates

Recent updates

Shareholder Returns

BNNDE ChemicalsDE Market
7D1.2%0.1%0.3%
1Y-11.2%-9.0%6.9%

Return vs Industry: BNN underperformed the German Chemicals industry which returned -9.1% over the past year.

Return vs Market: BNN underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is BNN's price volatile compared to industry and market?
BNN volatility
BNN Average Weekly Movement13.2%
Chemicals Industry Average Movement3.7%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.7%
10% least volatile stocks in DE Market2.4%

Stable Share Price: BNN's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: BNN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1993319Aryan Moelkerwww.brain-biotech.com

BRAIN Biotech AG engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates in three segments: BioProducts, BioScience, and BioIncubator. The company offers enzymes and biocatalysts to produce food and beverages, wound care preparations or lubricants, and production of starch and bioethanol; and microorganisms as the functional biomass for optimized industrial production processes, recycling of the greenhouse gas CO2 as an industrial raw material, and urban and green mining for extraction of precious and rare earth metals.

BRAIN Biotech AG Fundamentals Summary

How do BRAIN Biotech's earnings and revenue compare to its market cap?
BNN fundamental statistics
Market cap€77.56m
Earnings (TTM)-€8.77m
Revenue (TTM)€56.26m

1.4x

P/S Ratio

-8.8x

P/E Ratio

Is BNN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BNN income statement (TTM)
Revenue€56.26m
Cost of Revenue€24.98m
Gross Profit€31.29m
Other Expenses€40.06m
Earnings-€8.77m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Jan 15, 2025

Earnings per share (EPS)-0.40
Gross Margin55.61%
Net Profit Margin-15.59%
Debt/Equity Ratio0%

How did BNN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/01 16:08
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BRAIN Biotech AG is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Laura Lopez PinedaBaader Helvea Equity Research